Helixmith Obtains Domestic Patent for Candidate Substance Preventing and Treating Inflammatory Bowel Disease

[Asia Economy Reporter Lee Gwan-joo] Helixmith announced on the 24th that it has obtained a domestic patent for ‘HX204,’ a candidate substance for the prevention and treatment of inflammatory bowel disease.

HX204 is a plant-based complex extract developed by Helixmith’s natural product research team. It is known to have excellent anti-inflammatory effects and to improve intestinal tight junctions and mucus secretion.

Inflammatory bowel disease is a condition characterized by unexplained abnormal chronic inflammation in the intestinal tract that repeatedly improves and relapses. It is classified into Ulcerative Colitis (UC) and Crohn’s Disease (CD). Once it occurs, it tends to become chronic, requiring lifelong treatment and management. One-third of patients progress to a severe stage within 10 years, and 10-15% undergo intestinal resection surgery.

Currently, the available treatment approach is to alleviate symptoms with medication and then suppress the condition to maintain stability. However, there are not many types of drugs available, and those with strong effects have concerns about side effects and high costs.

Yoo Seung-shin, CEO of Helixmith, said, “HX204 shows higher safety compared to existing drugs while demonstrating equivalent therapeutic efficacy. Since it has been recognized as a treatment substance for inflammatory bowel disease in this patent, expectations are high. We are currently conducting preclinical studies and preparing to enter clinical trials in 2022.”

This content was produced with the assistance of AI translation services.